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The pandemic spread of obesity and its related complications is rapidly changing the epidemiology 
of many type of cancers, including Hepatocellular Carcinoma (HCC). Non Alcoholic Fatty Liver 
Disease (NAFLD) is becoming a main source of HCC, with a steadily rising trend compared to 
chronic hepatitis due to Virus B, C and alcohol. The much larger spread of the underlying liver 
disease in the general population and the chance of arising in non-cirrhotic liver are the most 
worrisome aspects of HCC in NAFLD. Effective screening programs are currently hampered by the 
limited knowledge of the pathways of carcinogenesis and the lack of tools able to stratify the risk in 
the NAFLD population. Hence poor surveillance has prevented an adequate treatment of NAFLD-
related HCC so far. Systemic and hepatic molecular mechanisms involved in hepatocarcinogenesis 
as well as potential early markers of HCC are being extensively investigated. This review describes 
the current clinical impact of HCC in NAFLD and discusses the most important unmet needs for its 
effective management. 
 
Word count: 166  
INTRODUCTION  
NAFLD is a complex condition encompassing much more than just liver disease, but in specific - 
albeit partially unknown - conditions, the liver becomes the target of multiple hits stemming from a 
deranged metabolism, ultimately leading to cirrhosis and risk of primary liver cancer. 
Hepatocellular carcinoma (HCC) stands as the most overlooked complication of NAFLD and 
probably the most challenging in clinical practice. This is mainly caused by the large burden of the 
underlying liver disease, by the chance of HCC in the absence of cirrhosis and by the limitations to 
treatment due to cardiovascular and metabolic comorbidities. The incomplete knowledge of the 
mechanisms leading to carcinogenesis in NAFLD hampers the development of markers for 
targeting subjects at high-risk and contributes to impede an effective care of NAFLD patients with 
HCC. The aim of this review is to provide updated hints on the surveillance and management of 
HCC in NAFLD and to highlight the most important unmet needs. 
 
THE BURDEN OF HCC IN NAFLD: PRESENT AND FUTURE 
What is currently known from epidemiological data gives us a perception of the alarming growth of 
NAFLD as cause of HCC, but does not reliably quantify the entity of the problem, particularly in 
non-cirrhotic patients. The first evidence of an association between NAFLD and HCC dates back at 
1990 (1). Since then, NAFLD is the source of HCC most rapidly increasing, in parallel with the 
spread of obesity and diabetes across the general population (2, 3). Most data come from cohort 
studies of HCC management and treatment and from liver transplant databases, while only few 
population-based studies are available (4-6)(Table 1). In a large study of HCC management in real-
world setting including 18031 patients with HCC in 14 countries (2005–2012), NAFLD accounted 
for 10–12% of underlying liver diseases in Europe and North America  (7). According to data from 
the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database between 2004 
and 2009 (8), NAFLD represented the third most common cause of HCC, after hepatitis C and 
alcohol-related disease, being diagnosed in 14.1% of patients with HCC. During the 6-year study 
period, an overall 9% annual increase in patients with NAFLD was reported, compared with a 13% 
increase in patients with hepatitis C. In a United States population-based study, NAFLD was 
classified as the most common risk factor for the development of HCC (59%) with a cumulative 
incidence of 0.3% over a 6-year follow-up (9). In another prospective community-based study 
which evaluated the outcomes of NASH patients with severe fibrosis (10), 11.3% of cirrhotic 
patients developed HCC after a mean follow-up of 7.6 years. 
The growing importance of HCC arising in NAFLD is more evident in tertiary centers and it will 
become obvious after the decline of HCV infection thanks to direct-acting antivirals therapy, 
although it will take decades to occur. A seminal study conducted in Newcastle upon Tyne (U.K.) 
between 2000 and 2010, reported a more-than-tenfold increase in HCC associated with NAFLD, 
accounting for 34.8% of all the cases in 2010 and making NAFLD the single most common 
underlying etiology (11). Similarly, a study from Germany, which analyzed 162 cases of HCC, 
identified steatohepatitis as the underlying etiology in 24% of patients, surpassing chronic hepatitis 
C (23.3%), chronic hepatitis B (19.3%), and alcoholic liver disease (12.7%) (12). A prospective 
study assessing 195 OLT candidates for NAFLD-related cirrhosis in from 2003 to 2007 reported an 
HCC incidence of 12.8% over a median follow-up of 3.2 years, with a yearly cumulative incidence 
of 2.6% (13). Hence, it is not surprising that NAFLD is the most rapidly increasing indication for 
liver transplantation (LT) due to HCC in U.S. According to the United Network for Organ Sharing 
(UNOS) registry (14), from 2002 to 2012 the number of NAFLD-related HCC increased of 364%, 
becoming the second leading cause of LT after HCV-related cases.  
Most studies suggest that the risk of HCC occurrence in NAFLD is lower than in chronic hepatitis 
C; for example, in a ten-year prospective study, HCC developed in 10 out of 149 patients with 
NAFLD-associated cirrhosis compared to 25 out of 147 patients with hepatitis C-associated 
cirrhosis (15). Overall, the 1-year cumulative incidence of HCC in patients with NAFLD has been 
estimated at around 2.5% compared with 4% in patients with hepatitis C, while the 5-year incidence 
rises to 11% and 30% respectively (16). However, the lower prevalence and incidence of HCC in 
NAFLD must be outweighed by the much larger spread in industrialized countries and the steady 
rise of its risk factors also in developing countries.  
Importantly, HCC can also develop in non-cirrhotic NASH, with hundreds of cases reported so far. 
The initial observation had been made in a single-center pathological study on 128 patients 
undergoing liver resection for HCC between 1995 and 2007 (17); HCC arising in livers without 
significant fibrosis occurred more frequently in patients with metabolic syndrome (MetS) and 
NAFLD (65.5%) than in patients with known liver disease of other origin (25%). This peculiar 
feature has been afterwards confirmed by epidemiological studies. In a U.S. Veterans 
Administration cohort (18) including 1500 patients with HCC from 2005 to 2010, 194 patients 
(13%) had no evidence of cirrhosis but had a higher prevalence of MetS and NAFLD. In the same 
cohort, the risk of HCC in the absence of cirrhosis was 5-fold higher in patients with NAFLD, 
compared to those with chronic hepatitis C. In a tertiary center for HCC referral in Northern 
England (11), those with NAFLD as underlying liver disease had a lower prevalence of cirrhosis 
(77.2%) compared with other etiologies. Similar observations have been confirmed in two Japanese 
studies, where cirrhosis was absent in 38% of 292 (19) and 49% of 87 patients (20) with NAFLD-
related HCC respectively.  
 Future projections of this scenario must take into account the alarming growth of NAFLD in the 
pediatric population, bearing an increased risk of liver related complications in adulthood. A 
longitudinal study (21) including Danish schoolchildren aged 7-13 years showed that each unit 
increase in BMI z-score will rise by 20–30% the risk of liver cancer 30 years later. In other words, 
this means that a 13-year-old boy who weighs 6 kg more compared to a lean boy of similar height 
would have a 30% increased risk of HCC in his mid-life. Similarly, a study in U.S. (22) reported 
that each unit increase in BMI in the mid-twenties can hasten by four years the occurrence of liver 
cancer, confirming that obesity in early adulthood is associated with increased risk of developing 
HCC at a younger age in the absence of other relevant risk factors. 
 
These data on one hand highlight once again the importance of a global policy for the prevention of 
obesity and its related complication since childhood, but on the other cast a shadow on the 
usefulness of our current tools for tracking NAFLD patients at high risk for HCC. Effective markers 
can only stem from the knowledge of the most important risk factors and mechanisms for the 
development of HCC in NAFLD. 
 
MULTIPLE HITS FOR THE DEVELOPMENT OF HCC IN NAFLD 
Beyond advanced liver disease itself and male gender, several other factors do concur to increase 
the risk of HCC in NAFLD and can translate into the unpredictable onset of cancer even in a non-
cirrhotic liver, which is one of the main dilemma of clinical management. 
 
Obesity and Type 2 Diabetes 
Obesity and Type 2 Diabetes (T2DM) have a well-established, independent and cumulative impact 
in the development of HCC, also in cirrhosis of viral and alcohol-related etiology, as reported in 
several large-scale epidemiological studies (Table 2), (23, 24). In a seminal population study 
including 900000 patients in the United States (23), the likelihood of dying from liver cancer in 
men with a body mass index (BMI) of 35 kg/m2 or above over 16 years of follow up was increased 
by 4.5-fold compared to the reference group with a normal BMI (18.5 to 24.9 kg/m2). A more 
recent study in U.K. analyzed primary care data from 5.24 million individuals in the Clinical 
Practice Research Datalink and found that BMI was positively associated with liver cancer (HR 
1.19, 99% CI 1.12-1.27) but this effect varied by subject’s individual characteristics. The 
association between BMI and liver cancer was more marked in men than women; in men, the risk 
substantially and linearly increased starting from BMI above 22 kg/m2, whereas in women more 
modest increases in risk were recorded. Assuming causality, 10% or more of liver cancers in the 
general population could be attributable to excess weight (25). A meta-analysis of 11 cohort studies 
estimated that the risk of HCC is increased by 17% in overweight and by 89% in obese subjects, 
with an average 24% increase in risk for each 5 kg/m2 increase in BMI; when considering males 
only, the risk of HCC in obesity rises up to 300%  (26).  
The association of obesity and risk of incident HCC has an ethnic specificity, as it is observed in 
white Caucasian, Latino and Asian men, but not in Afro-Americans, suggesting that we should 
move beyond BMI and evaluate fat-specific depots (27). Visceral fat accumulation is likely to play 
an important role, particularly in the non-obese population. In the EPIC (European Prospective 
Investigation into Cancer) cohort, the waist-to-hip ratio, a rough estimate of abdominal fat, 
predicted better than BMI the incidence of HCC over an 8.6-year follow-up and conferred a three-
fold HCC risk to subjects in the upper tertile (28).  
Similarly to obesity, in diabetes the risk of malignancy is increased by 20% and it is mostly 
accounted by HCC (29), with a hazard ratio (HR) of 2.24 in males and 1.94 in females. In an 
epidemiological study which included 14% of the United States population, T2DM was associated 
with a three-fold risk of HCC (30). A meta-analysis indicates a 2.5-fold increase in both HCC 
prevalence and incidence among patients with T2DM compared with non-diabetic controls, 
although it is unclear whether diabetes preceded the underlying chronic liver disease (31). 
The independent risk of HCC conferred by obesity and diabetes is clear in liver disease related to 
HBV, HCV and alcohol, but not obvious in NAFLD where the features of MetS also promote the 
onset and progression of the liver damage. In U.K. the rise in cancer incidence and in cases 
attributed to NAFLD was paralleled by a steady increase of MetS in patients with HCC (11). An 
Italian multicentre case-control study tried to assess the role of each feature of MetS as HCC 
promoter in 185 cases of HCC compared with 404 controls (32). In this analysis T2DM was 
associated with the highest risk for HCC (OR 4.33, 95% CI 1.89–9.86), followed by obesity (OR 
1.97, 95% CI 1.03–3.79) and overweight (BMI ≥25 kg/m²)(OR 1.25, 95% CI 0.72–2.18), while no 
link was observed with hypertension and hypercholesterolaemia. Combining multiple hallmarks of 
MetS, the risk of HCC increased in parallel with the number of features considered, reaching an OR 
of 4.75 (95% CI 1·75–12·89) in patients who were overweight and had diabetes (32).  
 
Genetic background 
Multiple risk factors related to host phenotype significantly interact with the genetic background to 
increase the risk of malignancy. The polygenic inheritance of metabolic diseases, including 
NAFLD, makes difficult the identification of a single genetic mutation responsible for the increased 
risk of HCC. Nevertheless, the PNPLA3 rs738409 [G] risk allele, found in 40% of the European 
population, is repeatedly reported to increase about twelve-fold the risk of developing HCC (33); 
further, among HCC patients, GG homozygosity is also associated with younger age, shorter history 
of cirrhosis or less advanced liver disease, and more diffuse HCC at diagnosis, hence reduced 
survival. Other uncommon genetic variants seem to influence HCC development in a fatty liver. 
The most important is the human telomerase reverse transcriptase (TERT) gene, which is 
upregulated in human cancer and is a hallmark of HCC in patients carrying loss-of-function TERT 
mutations (34). Although only a few Single Nucleotide Polimorfisms (SNPs) have been associated 
with the development of HCC, they are clinically relevant for potential use as markers of HCC in 
NAFLD in addition to clinical factors, favoring the implementation of screening strategies for high 
risk patients (35).  
 
Other risk factors 
The combination of metabolic and genetic risk factors above described could be a fertile soil for the 
malignant degeneration of benign liver lesions, such as hepatocellular adenomas (HCA), also in the 
absence of cirrhosis. In a French study which analyzed 31 HCC patients who had MetS as the only 
risk factor, one-third of these cases developed in a preexisting hepatocellular adenoma (36), while a 
literature review of 1600 adenomas showed that nearly 4% of them presented HCC features at the 
time of resection (37). There is an association between the rising prevalence of obesity and MetS 
and the recent increase in the HCA prevalence, more likely Inflammatory (I-HCA) (38,39). Obesity 
and MetS has been often associated with multiple and bilobar adenomas, leading to a higher rate of 
incomplete resection, and with progression of HCA; conversely, stability or regression of tumor 
burden is described in up to one third of patients complying with lifestyle changes (weight 
loss>5%) (38). As a result, the prevalence of malignancy within HCA has markedly increased in 
men since 2000 and MetS has become the most frequent associated condition.  
 
Potential molecular mechanisms 
Mechanisms linking the progression of steatosis to HCC, with or without cirrhosis, are probably 
more related to the pathogenesis of the underlying disease rather than to fibrosis, with an important 
role attributed to environmental factors leading to obesity and diabetes. Western high-fat diet can 
induce the expression of cytokines like IL-6 and TNFα and increase NF-κB activation (40). In a 
mouse model, disruption of CD4+ mitochondrial function by linoleic acid boosts oxidative damage 
via high levels of reactive oxygen species (ROS) generated by CD4+ lymphocytes, while on the 
contrary blockade of ROS can delay the development of HCC (41). Fructose may play an important 
role by increasing lipoperoxidation (42), downregulating the expression of sirtuin-1, involved in the 
regulation of cellular survival, or altering the intestinal microbioma composition (43). Gut 
microbioma contributes to hepatic inflammation by increasing intestinal permeability, promoting 
translocation of bacterial components such as lipopolysaccharides and favoring the activation of the 
toll-like receptors.  
Figure 1 summarizes the possible impact of the risk factors above described over the development 
of HCC during a lifetime. 
 
HCC SURVEILLANCE IN NAFLD: MORE QUESTIONS THAN ANSWERS 
Poor surveillance is a constant problem for NAFLD patients and liver-related complications can be 
the presenting features. In a multicenter prospective study in secondary care Italian centers (44), 
which included 756 patients with HCC related either to NAFLD or HCV, 63% of patients with 
NAFLD missed regular surveillance compared with patients with hepatitis C (p<0.0001), resulting 
in more advanced HCC burden at diagnosis. In a national U.S. cohort study from Veterans 
Administration hospitals, including 1500 patients who developed HCC from 2005 through 2010, 
the diagnosis was made by surveillance in only 40% of patients with NAFLD compared to 80% of 
patients with hepatitis C (45). An effective surveillance is further hindered in patients without 
cirrhosis. In a retrospective analysis of patients diagnosed with HCC in NAFLD between 2003 and 
2012, 86% of patients with HCC in non-cirrhotic liver had a larger nodule size and/or a greater rate 
of recurrence compared with 14% of patients with HCC in cirrhosis (36). Similarly, in another case 
series of 44 patients who developed NAFLD-related HCC between 2010 and 2012,  only one 
patient (out of six) without cirrhosis underwent liver resection, while the late diagnosis impeded 
curative treatments in the others (46). 
Programming an optimal screening strategy for the early detection of HCC in NAFLD is not trivial. 
According to current knowledge, the phenotype of patients with NAFLD at risk for HCC is 
predominantly that of an obese male, with history of diabetes and cardiovascular comorbidities, 
significantly older than patients with HCC of other origins (47,68). This phenotype consistently 
overlaps with the definition of NAFLD patients that should be screened for NASH according to the 
recent European clinical practice guidelines (48), and share the same problems: the burden of 
potential candidates for systemic surveillance and the absence of reliable non-invasive tools and 
molecular signatures able to stratify the risk in the NAFLD population, de facto leaving many 
patients undiagnosed and untreated. On top of that, the onset of HCC in non-cirrhotic livers has led 
to further uncertainties. In consequence, specific recommendations for the surveillance for HCC in 
patients with NAFLD are currently lacking. The practice of oncologic follow-up on an individual 
basis is supported by three out of five guidelines on the management of NAFLD (48, 49, 50). The 
guidelines of the Asia-Pacific region suggest the extension of screening to those “cancers whose 
incidence is increased by MetS,” but without a generalized and standardized program. The most 
recent EASL-EASD-EASO clinical practice guidelines still indicate that the large number of 
NAFLD cases at risk of HCC makes systematic surveillance largely impracticable (48).  
Surveillance is deemed as cost-effective if the expected risk for incident HCC exceeds a threshold 
of 1.5% per year, but epidemiological studies are still inadequate to answer this question. The 
PNPLA3 rs738409 C>G gene polymorphism might provide patient-risk stratification for tailored 
HCC surveillance in NAFLD, but it is not considered cost-effective yet (48). Therefore, HCC 
arising in NAFLD is not reported as a separate identity but included into “other conditions” in the 
AASLD guidelines for management of HCC (49). However, surveillance by abdominal ultrasound 
has a suboptimal performance in this kind of patients, with a high rate of under-recognition of small 
nodules (51, 52).  
Imaging based criteria for the diagnosis of HCC in non-cirrhotic patients is advised only in chronic 
hepatitis B, while there is no recommended screening practice in subjects with NASH (49,53). 
Thus, in this specific subgroup the diagnosis of HCC should be established by liver biopsy. Recent 
findings suggest that some HCC developing in NAFLD patients could belong to a particular 
subtype of hepatic tumors with distinct histological features, called “steatohepatitic hepatocellular 
carcinoma”, characterized by histological hallmarks resembling steatohepatitis, such as steatosis, 
hepatocyte ballooning, Mallory bodies, and peri-hepatocellular fibrosis (54). However, liver biopsy 
should be the final step of a well-defined pathway, starting from tracking high-risk subgroups. 
Recently a scoring system based on age, sex, medical history of diabetes and viral hepatitis, 
aminotransferases and α-fetoprotein was able to identify almost all HCC cases detected by 
ultrasound in Taiwan high-risk patients (55). The most successful disease management programs 
are those where both the pathogenesis and the natural history of the disease are well understood, 
thus requiring the joint efforts of clinical and basic researchers to hopefully improve the early 
identification of HCC in targeted NAFLD patients. 
 
TREATMENT OF HEPATOCELLULAR CARCINOMA AND OUTCOME IN NAFLD 
PATIENTS 
Most recent guidelines give the same therapeutic indications for the treatment of HCC (liver 
transplantation, radiofrequency ablation, chemioembolization, sorafenib), regardless of its etiology 
(53).  However, the first logic consequence of poor surveillance in NAFLD patients is a diminished 
likelihood of successful treatment for HCC. In the SEER database (8), including 5,748 HCC cases 
of various etiology between 2004 and 2009, factors associated with one-year mortality after HCC 
diagnosis were older age (HR: 1.02), lower income (HR: 1.33), un-staged tumor (HR: 1.24) and 
NAFLD (HR: 1.21). In a U.K. referral center for the management of HCC (11), where just 23% of 
patients with NAFLD have their HCC detected by surveillance, the majority (62.3 %) presented 
symptomatically, with larger tumors and at a more advanced TNM stage, so that their median 
survival was just 7.2 months. Furthermore, locoregional treatments can be limited by technical 
difficulties in ultrasound detection or by peripheral atherosclerosis, while increased risks for 
infection, metabolic decompensation and cardiovascular complications can hamper surgical options 
(56). The drawbacks of older age, higher rate of cardiovascular and metabolic comorbidities and 
higher rate of unresectable HCC can be partially outweighed by a better preserved liver function or 
a lower prevalence of cirrhosis in these patients. Thus, in the above mentioned study (44), 19% of 
patients with NAFLD-related HCC underwent  liver resection compared with 11% of those with 
hepatitis C. The same observation had been done in a retrospective cohort in USA assessing the 
outcome of curative treatments for HCC (34): NAFLD patients had a better hepatic synthetic 
function than patients with hepatitis C or alcohol-related liver disease, and were more likely to 
undergo liver resection (41%  in the NAFLD group compared with 13% in the hepatitis C and 
alcohol-related liver disease group, p=0.002). 
In accordance with these data, recent findings suggest that NAFLD patients do not have a different 
morbidity and mortality compared to other etiologies after surgical treatment for HCC. In a 
retrospective study comparing NAFLD and HCV patients with HCC, the main predictors of severe 
morbidity and liver failure rates after liver resection were cirrhosis, major hepatectomy and MELD 
>8, but not steatohepatitis (57). Similar observations were made in another study which evaluated 
the outcome of HCC treatment in 303 patients from 2000 to 2010. After a median follow up of 50 
months, no difference was found in recurrence-free survival and overall survival between NAFLD 
and HCV or alcohol-related HCC, independent of other pathologic factors and type of curative 
treatment (34). Importantly, from 2002 to 2012 the indication for LT in patients with HCC and 
NAFLD has increased by nearly fourfold compared to a twofold increase in those with HCV-related 
HCC (14). However, patients with NAFLD in waiting list for LT usually have a lower MELD score 
compared with other liver diseases (58). Thus, according to the UNOS database for LT between 
2004 and 2013, they are less likely to receive a liver graft at 90 days and one year after registration 
than patients with HCV or alcoholic liver disease (58). Very high BMI, especially morbid obesity, 
represents a contraindication to LT and some centers begin to consider obesity treatment like 
bariatric surgery as preparation for LT. Even though it might be difficult or impossible in patients 
with end-stage liver disease, preliminary results suggest that combined LT along with sleeve 
gastrectomy might be considered in selected cases (59). After LT, the five-year survival in NAFLD 
does not differ from non-NAFLD because the greater risk of death from cardiovascular 
complications and sepsis is outweighed by a lower risk of graft failure (60). 
 
PREVENTION OF HCC IN NAFLD: SOMETHING POSSIBLE? 
Given the burden of the underlying liver disease, it is likely that the crude cost of any screening 
program will be exceedingly high for healthcare resources, thus prevention is an option to be 
actively pursued. Despite many uncertainties, available knowledge suggests that HCC in NAFLD 
develops slowly during a lifetime; however, the earlier the exposure to risk factors, the earlier the 
onset of malignancy, particularly on a genetically predisposed background. The casual association 
with other “superimposed hits” along the trajectory to HCC (such as virus, alcohol or adenomas) 
could hasten its progression (Figure 1). Hence, much of the game is played in the preliminary 
phases of the liver disease.  
First of all, prevention of obesity starting from childhood should be a priority in the agenda of 
educational programs (particularly in the schools), and of health care providers, including primary 
practitioners and pediatric specialists. Lifestyle modification can be able itself to change the natural 
history of the disease. In a prospective cohort study in Taiwan analyzing risk prediction models for 
HCC (n=428584, HCC=1668) during an average follow-up of 8.5 year, physical activity reduced 
the risk of developing HCC proportionally to the intensity of exercise and regardless to the etiology 
of liver disease (61). In another Swiss study on the development of HCC in hepatocyte-specific 
PTEN-deficient mice with steatosis, regular exercise reduced the mean number and the volume of 
lesions and decreased tumor cell proliferation, stimulating the phosphorylation of AMPK and 
decreasing the kinase activity of mTOR (62). 
Second, effective therapies to cure NASH can reduce the burden of patients at high risk for 
developing HCC. The landscape of potentially curative treatments is rapidly growing, as reviewed 
elsewhere in this issue (..Editorial office)  
Lastly, we should not forget possible prevention of HCC by old drugs often prescribed in NAFLD 
patients. Metformin seems to enhance antitumour mechanisms by mTOR inhibition (63). In a meta-
analysis the use of metformin in 105495 patients with T2DM was associated with a 70% reduction 
in the risk of HCC (64). A reduction of 50% in HCC risk was also observed in another meta-
analysis including 22650 HCC-patients among 334307 diabetics, while the risk was increased when 
sulfonylurea or insulin were used (65). Further, metformin can even improve the outcome of HCC 
treatment: in a prospective Taiwanese study in diabetic patients with early stage HCC undergoing 
radiofrequency ablation, a lower mortality rate was observed in patients under metformin (66). 
Increasing data also highlight an important role for statins: in a large  meta-analysis which collected 
4298 cases of HCC among 1.5 milion patients, the use of statins has been associated to a 37% 
reduction in HCC incidence (67). All these data suggest that the use of these medications should be 
encouraged in patients with NAFLD beyond their metabolic and cardiovascular benefits. 
 
 CONCLUSIONS  
The growing burden of HCC linked to NAFLD is becoming a serious challenge for public health, in 
terms of surveillance and treatment. Many questions remain to be answered, including 
carcinogenesis in non-cirrhotic livers and the best strategy for targeting high-risk subjects in the 
general population. These open problems currently delay diagnosis and limit the possibility of 
therapeutic intervention. We need more epidemiological and clinical data and a better 
understanding of the molecular events leading from obesity to NASH and HCC, particularly in non-
cirrhotic patients, in order to develop scoring algorithms and serological tests to stratify the risk in 
NAFLD patients. In the meanwhile, the best and probably sole effective strategy is prevention of 
the main risk factors for NAFLD through public awareness and education programs. 
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Table 1. Principal and most recent studies about the association between NAFLD/NASH and 
HCC. 
Author Study Subjects Results and Comments 
 
HCC in NAFLD/NASH-related cirrhosis 
Bugianesi 2002 (69) Analysis of 44 CC among 641 
patients with cirrhosis of different 
etiologies 
In CC-related HCC high prevalence 
of features of MS have been observed 
(T2DM, obesity, dyslipidemia). 
NAFLD-related features are more 
frequent in HCC arising in CC than 
HCC of other origins. 
Marrero 2002 (70) Analysis of 105 HCC patients.  NAFLD prevalence among CC-
related HCC was 13%. CC-related 
HCC were less likely to have 
undergone HCC surveillance and had 
larger tumors at diagnosis 
Mittal 2015 (45) 1.500 patients who developed HCC 
from 2005 through 2010 from 
Veteran Administration hospitals 
NAFLD accounted for 8% of total 
cases. A higher percentage of 
NAFLD-related HCC were not 
diagnosed during surveillance 
programs. NAFLD is the third most 
common risk factor for HCC 
Wong 2014 (2) 10.061 American adults LT liver 
recipients for HCC (2002-2012). A 
retrospective study.  
From 2002 to 2012, the number of 
patients undergoing LT for NASH-
related HCC increased 4 folds, much 
more than any other HCC etiology. 
Tateishi 2015 (71) 33.782 HCC cases in 53 tertiary care 
centers in Japan from 1991 to 2010 
The proportion of non-virus-related 
HCC cases increased from 1991 to 
2010 (10.0% to 24.1%) and most 
cases of non-viral HCC are related to 
lifestyle factors, including obesity 
and T2DM 
 
HCC in non-cirrhotic liver with NAFLD/NASH 
Paradis 2009 (17) 31 HCC patients with MS and no 
cirrhosis or causes of cirrhosis 
HCC arising in the context of MS 
were more often well differentiated 
(28% vs 64.5%) and in one third of 
cases developed in a preexisting liver 
cell adenoma 
Yasui 2011 (20) 87 HCC cases in a Multicentre 
Japanese study on histologically 
proven NASH 
HCC arises in 43 cases with no 
established cirrhosis 
Dyson 2014 (11) 632 English patients with HCC 
analyzed between 2000 and 2010 
Most commonly, HCC arising 
without cirrhosis are linked to 
NAFLD. Diagnosis was made out of 
surveillance programs, so patients 
presented larger tumors associated 
with symptoms.  
Perumpail 2015 (46) 
 
NAFLD/NASH-associated HCC 
arising in the absence of cirrhosis 
between January 2010 and September 
2012 from a tumor board database at 
Brooke Army Medical Center 
(BAMC). 
Of 44 cases of HCC reviewed, 6 
cases of non-cirrhotic HCC 
associated with NAFLD/NASH 
and/or MS were identified.  
The development of this kind of HCC 
in the absence of cirrhosis in the US 
population raises the important 
question of HCC screening for this 
at-risk group. 
Mohamad  2015 (36) A retrospective analysis on all adults 
diagnosed with HCC and NAFLD at 
Cleveland Clinic Foundation between 
2003 and 2012. 
36 patients with non-cirrhotic 
NAFLD-HCC were compared to 47 
patients with NAFLD-HCC and liver 
cirrhosis.  
Patients with HCC in the absence of 
cirrhosis are more likely to present at 
an older age with larger tumor and 
have higher rates of tumor 
recurrence. 
Studies to assess the cost-
effectiveness of HCC surveillance in 
this group should be conducted 
 
CC: cryptogenic cirrhosis; HCC hepatocellular carcinoma; BMI: body mass index; MS: metabolic syndrome; NAFLD: 
non-alcoholic fatty liver disease; T2DM: type 2 diabetes mellitus; TG: triglycerides; AST: aspartate aminotransferase; 







Table 2. Principal and most recent studies about the association between HCC, obesity and 
Type 2 Diabetes mellitus.  
 
Author Study subjects Results 
HCC and obesity 
Calle 2003 (23) Cohort of 900.000 American adults Risk of dying from HCC was 4.5 times 
higher in men with a BMI >35  compared 
to the group with normal BMI. RR 2.41 in 
men (95% CI 1.92-3.01) and 1.47 in 
women (95% CI 1.08-2) 
Larsson 2007 (26) Meta-analysis of cohort studies of 
excess body weight and risk of 
HCC from 1966 to 2007 
Summary RR of HCC was 1.17 (95% CI 
1.02-1.34) for overweight subjects and 1.89 
(95% CI 1.51-2.36) for the obese 
Schlesinger 2013 (28) European multicenter trial with 
359.525 subjects 
Weight increase in adulthood was found to 
be a risk factor for HCC (RR 2.48, 95% CI 
1.49-4.13) 
Archambeaud 2014 (72) 
 
 
905 HCV/HBV negative Caucasian 
patients with alcoholic or 
metabolic cirrhosis collected in 
four French centres. 
HCC was independently related to past 
obesity (P = 0.007) and diabetes 
(P = 0.037).  
 
Manal M. Hassan 2015 (22) 
 
 
622 patients newly diagnosed with 
HCC from 2004 to 2013, compared 
to 660 healthy controls to 
determine weights, heights, and 
body sizes at various ages before 
HCC development or enrollment as 
controls. 
Obesity in early adulthood  is a significant 
risk factor for HCC (OR 2.6, 95% CI 1.4–
4.4 for entire population, 2.3, 95% CI 1.2-
4.4 for men and 3.6, 95% CI 1.5–8.9, for 
women respectively). 
Each unit increase in BMI at early 
adulthood was associated with a 3.89-
month decrease in age at HCC diagnosis (P 
<.001). 
Setiawan 2016 (27) 
 
 
Cohort study of more than 215,000 
men and women from Hawaii and 
California that was assembled 
from 1993 through 1996. After a 
median follow-up of 16.6 years, 
482 incident HCC cases were 
identified among 168,476 
participants. 
BMI was associated with HCC in men (HR 
1.26; 95% CI, 1.12–1.42) but not in women 
(HR, 1.06; 95% CI, 0.90–1.25) and only in 
Japanese, white, and Latino men, while 
there was no association in black men. 
 
HCC and type 2 diabetes mellitus 
 
Davila 2005 (30) 2.061 HCC patients and 6.183 non-
cancer controls from the 
Surveillance Epidemiology and 
End-Results Program-Medicare 
linked database. Population-based 
case-control study 
The proportion of HCC patients who had 
diabetes (43%) was significantly greater 
than controls (19%). Diabetes increased the 
risk for HCC (adjusted OR 2.87, 95% CI 
2.49-3.30) 
Inoue 2006 (29) Questionnaire to 97.771 Japanese 
subjects 
Diabetes led to a higher risk of HCC in 
males and females (HR of 2.24 CI 95% 
1.64-3.04 and 1.94 CI 95% 1.00-3.73, 
respectively) and was more strongly 
associated with development of HCC 
among malignant tumors 
Koh 2013 (74) 
 
A prospective cohort of 63.257  
Chinese men and women enrolled 
in 1993–1998. After a mean 
follow-up of 14 years, 499 cohort 
participants developed HCC. 
A history of diabetes at baseline was 
associated with an HR of 2.14 (95% CI 
1.69–2.71). 
Kasmari 2017 (73) 
 
A retrospective cohort study, using 
the MarketScan insurance claims 
database from 2008-2012. 
Individuals with HCC (7.473 
patients) aged 19-64 years and age 
and sex-matched controls (22.110 
patients) were included 
In the absence of cirrhosis, type II diabetes 
(OR 1.353) was an independent risk factor 
for hepatocellular carcinoma. 
 
CC: cryptogenic cirrhosis; CI: confidence interval; HCC hepatocellular carcinoma; RR: relative risk; OR: odds ratio; 
BMI: body mass index; MS: metabolic syndrome; SIR: standardized incidence ratio; NAFLD: non-alcoholic fatty liver 












Figure 1. Impact of the main risk factors over the development of HCC during a lifetime.  
HCC in NAFLD develops slowly during a lifetime; however, the earlier exposure to risk factors, as 
childhood obesity, and a genetically predisposed background can hasten its progression and/or 
increase the risk. The casual association with other “superimposed hits” along the trajectory to HCC 
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